Elanco Animal Health Inc. — Q2 2023 Form 10-Q
Reporting period: Quarter and six months ended June 30, 2023. Elanco is a global animal-health company operating in one segment, with Pet Health and Farm Animal product categories. Unless stated otherwise, amounts are in millions of U.S. dollars.
Financial results
| Metric | Q2 2023 | Q2 2022 | Six months 2023 | Six months 2022 |
|---|---|---|---|---|
| Revenue | $1,057 | $1,175 | $2,314 | $2,401 |
| Gross margin | 59% | 59% | 60% | 59% |
| Net income (loss) | $(97) | $(10) | $6 | $41 |
| Diluted EPS | $(0.20) | $(0.02) | $0.01 | $0.08 |
| Operating cash flow | Not separately presented for the quarter | $(84) | $250 |
Q2 revenue fell 10% year over year; first-half revenue fell 4%. Q2 Pet Health revenue declined 15% to $518, while Farm Animal declined 5% to $527. For the first half, Pet Health declined 5% to $1,193 and Farm Animal declined 2% to $1,100. Q2 cost of sales was 41% of revenue, unchanged year over year; first-half cost of sales improved to 40% from 41%.
Q2 interest expense increased 10% to $74; first-half interest expense increased 16% to $138. Asset impairment, restructuring and other special charges were $35 in Q2 and $75 for the first half, versus $86 and $126, respectively, in 2022. Q2 other expense included a $15 Seresto litigation accrual. The six-month effective tax rate was 79.9%, reflecting jurisdictional earnings mix and losses for which tax benefits were not recognized.
Financial position and liquidity
- At June 30, cash and cash equivalents were $367, versus $345 at year-end 2022. Current assets were $3,652 and current liabilities $1,284.
- Total debt was $6,062, including $250 drawn on the revolving credit facility; the reported long-term debt balance was $6,023. Debt increased from $5,836 at December 31, 2022. The company reported compliance with debt covenants.
- First-half operating cash use of $84 compared with cash provided of $250 in 2022. Management attributed the decline mainly to working-capital changes, particularly receivables and inventory, and the nonrecurrence of $132 in interest-rate-swap settlement proceeds received in 2022. Investing cash use was $98; financing provided $213.
- At June 30, unused revolving-credit capacity was approximately $500. After quarter-end, Elanco drew $250 under a new, three-year receivables-backed facility and $100 on its revolver, then redeemed its $344 of 4.272% senior notes due 2023. The filing states that approximately 75% of long-term indebtedness was fixed-rate after these transactions.
Material changes and management commentary
- Management estimated that ERP integration-related commercial shipping blackouts shifted approximately $90–$110 of revenue from Q2 into Q1 2023. The Q2 estimates were $65–$80 for Pet Health and $25–$30 for Farm Animal. Certain international customers also received extended payment terms on approximately $35 of Q1 sales.
- Management cited weaker retail parasiticide demand in some markets, U.S. competitive pressure, supply disruption in U.S. cattle vaccines, and regulatory changes and generic competition affecting cattle implants. Pricing partially offset volume and foreign-exchange declines.
- Management expected global macroeconomic pressures, including inflation, higher rates and supply-chain challenges, to continue through 2023. It anticipated additional Bayer integration costs during 2023; first-half integration costs totaled $75.
- Pet Health sales are seasonal, with a substantial share of annual Seresto and Advantage Family revenue historically occurring in the first half. Management cautioned that first-half results are not necessarily indicative of second-half performance. No specific full-year financial guidance is provided in the supplied filing text.
Risks, contingencies and unusual items
- Elanco accrued $15 for a potential settlement of consolidated Seresto class actions; settlement terms still required agreement on non-monetary matters and court approval. Separately, on July 13, 2023, the EPA confirmed continued registration of Seresto after its review and denied a citizen petition. Other lawsuits and an SEC inquiry concerning pre-mid-2020 channel inventory and sales practices remained unresolved; the company said it could not estimate potential loss for these matters.
- Elanco reported that disclosure controls remained ineffective because of a previously identified material weakness in review of the annual income-tax provision, including deferred-tax valuation allowances. Remediation was not expected to be fully assessable until year-end 2023.
- The company had $71 due from TriRx under prior manufacturing-site sale arrangements, including $65 classified as current. Payment timing was restructured; management considered the balance collectible but said it would continue to assess collectibility and monitor collateral.
- Goodwill was $6,040. Although market capitalization remained below book value at June 30, management’s qualitative reassessment did not change its conclusion that goodwill was not impaired; future impairment remains sensitive to valuation assumptions.
- Other exposures include substantial indebtedness and interest-rate risk, currency devaluations, competitive and product-safety risks, and a 25-year headquarters lease commitment with estimated minimum payments of approximately $378, expected to commence in 2025.
Most important facts for investors to verify
- Whether the ERP-related revenue timing shift unwinds as expected and how underlying demand and channel inventory develop.
- Whether working capital, especially receivables and inventory, converts to cash and whether liquidity remains adequate.
- The cost, terms and effect of the post-quarter debt refinancing, including interest expense and covenant headroom.
- Progress on the income-tax control remediation and any effects of the prior-period financial-statement revisions.
- Final Seresto settlement terms and developments in other litigation and the SEC inquiry.
- Collectibility and payment timing of the TriRx receivable, and whether goodwill or other intangibles face impairment.